Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass (GLIMMER)

April 15, 2026 updated by: University of Alberta

GLP-1 Receptor Agonist-Induced Loss and Impairment of Muscle Mass - Evaluation of Response

The aim of this study is to use advanced MRI scans to track changes in both muscle and fat in the body and heart over a 12-month period in individuals starting semaglutide. By doing so, we hope to gain a clearer understanding of how semaglutide affects muscle health and function. Our goal is to ensure the medication supports long-term well-being, particularly for people who may be at higher risk of muscle loss.

This study involves (3) in-person study visits. At each visit, participants will be asked to:

  • Undergo magnetic resonance imaging (MRI) while resting and during exercise to take pictures of their heart, abdomen, and legs.
  • Complete tests to assess balance, sit-to-stand, walking speed, and handgrip strength.
  • Complete questionnaires related to demographics, health information, physical activity, and nutrition.
  • Have a blood sample collected from a vein in your arm.
  • Have your blood levels assessed through three finger pricks.
  • Complete three days of food records.

Study Overview

Status

Recruiting

Conditions

Study Type

Observational

Enrollment (Estimated)

50

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • Canada
    • Alberta
      • Edmonton, Alberta, Canada, T6G 0M9
        • Recruiting
        • Mazankowski Alberta Heart Institute
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Individuals who are starting semaglutide and are able to attend study visits at the Mazankowski Alberta Heart Institute.

Description

Inclusion Criteria:

  • Adults 18-80 years of age
  • Starting semaglutide for type 2 diabetes or weight loss
  • Able to safely undergo an MRI scan (including meeting the physical requirements for MRI equipment)

Exclusion Criteria:

  • Current use of semaglutide for more than 2 weeks
  • Major recent heart issues or other severe health conditions
  • Concerns related to MRI use (including magnetic implants, pacemaker, severe claustrophobia)
  • Dependence on a mobility aid (unable to participate in exercise MRI)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Changes in skeletal and cardiac muscle mass
Time Frame: 12 months
12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Alberta

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

April 14, 2026

Primary Completion (Estimated)

December 31, 2027

Study Completion (Estimated)

April 30, 2028

Study Registration Dates

First Submitted

November 26, 2025

First Submitted That Met QC Criteria

November 26, 2025

First Posted (Actual)

December 9, 2025

Study Record Updates

Last Update Posted (Actual)

April 20, 2026

Last Update Submitted That Met QC Criteria

April 15, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Pro00153724

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Obesity

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zimbabwe

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe